Science Pool

CD40 and type-I interferon immune pathways by a bifunctional molecule in HBV infection models

Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). It is still a major public health problem with 250 million chronically HBV-infected patients worldwide with none of the current treatments leading to a cure.
More effective treatments are needed to achieve HBV cure in a large proportion of patients.
We aim to develop a treatment, combining simultaneous stimulation of CD40 and IFN-I pathway, which leads to a strong anti-HBV effect with minimal inflammation.

In this poster we:

  • Present the key results that demonstrated the potential of such combination to induce anti-HBV effects in vitro and in vivo
  • Introduce the design of our new antibody-based therapeutic that combine the two modalities in one single molecule
  • Demonstrate the efficacy of the molecule in HBV infection system in Primary Human Hepatocytes
  • Show key results from our preclinical safety assessment in vitro and in vivo in Non-Human Primate

Read our poster to learn more about our research!